7.75
-0.38(-4.67%)
Currency In USD
| Previous Close | 8.13 |
| Open | 8.12 |
| Day High | 8.29 |
| Day Low | 7.59 |
| 52-Week High | 8.98 |
| 52-Week Low | 4.55 |
| Volume | 309,926 |
| Average Volume | 413,345 |
| Market Cap | 623.22M |
| PE | -3.82 |
| EPS | -2.03 |
| Moving Average 50 Days | 7.88 |
| Moving Average 200 Days | 6.94 |
| Change | -0.38 |
If you invested $1000 in MeiraGTx Holdings plc (MGTX) since IPO date, it would be worth $516.67 as of October 19, 2025 at a share price of $7.75. Whereas If you bought $1000 worth of MeiraGTx Holdings plc (MGTX) shares 5 years ago, it would be worth $599.85 as of October 19, 2025 at a share price of $7.75.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MeiraGTx Announces Two Posters at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical-stage genetic medici
MeiraGTx Announces the Presentation of Four Posters at the American Society of Gene and Cell Therapy (ASGCT) 2025 Annual Meeting
GlobeNewswire Inc.
May 13, 2025 8:30 PM GMT
Multiple Poster Presentations Highlight the Depth and Novelty of MeiraGTx’s Technology Platforms for Gene and Cell TherapyLONDON and NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AAV-GAD for the Treatment of Parkinson’s Disease
GlobeNewswire Inc.
May 09, 2025 12:00 PM GMT
- This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits of the Fast Track and Breakthrough Therapy desi